Prime Medicine, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Prime Medicine, Inc. (PRME) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $5.86 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.83, a 21.13% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.66, a 25.28% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.59, a 31.82% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $17.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2026-06-30 | $5.86 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $6.83 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $7.58 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $7.04 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $8.66 10-Q · filed 2025-05-08 | ||
| 2024-09-30 | $11.02 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $11.34 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $11.59 10-Q · filed 2024-05-10 | ||
| 2023-09-30 | $8.82 10-Q · filed 2023-11-03 | ||
| 2023-06-30 | $8.36 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $17.00 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | $4.66 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |